BCL9 suppression leads to the engagement of CD226 which in turn activates of VAV1 and promotes CD155 expression possibly via increasing mRNA levels of Gli1 and Patch. BCL9 depletion also significantly decreases CCL22 expression in tumor cells. The gene discussed is CD226; the disease is neoplasm.